Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 79,305 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 2 Clear all
Completed Phase 3 Interventional Results available

Negative Pressure Wound Therapy in Post-Operative Incision Management

NCT02682316
View directory record Official record
Conditions
Negative-Pressure Wound Therapy
Interventions
dry gauze, The Prevena Incision Management System
Other · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
10
States / cities
Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Nov 5, 2026, 5:43 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)

NCT06698016
View directory record Official record
Conditions
Healthy
Interventions
Nemtabrutinib, Efavirenz
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Nov 5, 2026, 5:43 AM EST
Terminated Phase 1 Interventional Results available

Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.

NCT02936206
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, Tamoxifen
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Nov 5, 2026, 5:43 AM EST
Terminated Phase 3 Interventional Results available

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

NCT01601704
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NB32, PBO, Weight Management Program
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
45 Years and older
Enrollment
8,910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
224
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 221 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Nov 5, 2026, 5:43 AM EST
Terminated Phase 1 Interventional Results available

Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors

NCT03954704
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Dalutrafusp alfa, mFOLFOX6 Regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Nov 5, 2026, 5:43 AM EST
Completed No phase listed Observational

Clinical and Laboratory Analysis of Familial Cancer

NCT02565004
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
10 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Nov 5, 2026, 5:43 AM EST
Withdrawn Not applicable Interventional Accepts healthy volunteers

Vascular Pathophysiology in Obstructive Sleep Apnea

NCT00214084
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Allopurinol
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Nov 5, 2026, 5:43 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Patient Satisfaction With Propofol for Out Patient Colonoscopy

NCT02937506
View directory record Official record
Conditions
Colon Cancer, IBS, Polyps
Interventions
Propofol, Fentanyl Plus Midazolam
Drug
Lead sponsor
Mount Carmel Health System
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Nov 5, 2026, 5:43 AM EST
Completed Phase 2 Interventional

Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients

NCT00080106
View directory record Official record
Conditions
HIV Infections
Interventions
MRK Ad5 HIV-1 gag vaccine, Vaccine placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
27
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Nov 5, 2026, 5:43 AM EST
Completed Phase 4 Interventional Results available

Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder

NCT01010204
View directory record Official record
Conditions
Smoking Cessation, Bipolar Disorder
Interventions
Varenicline, Placebo
Drug
Lead sponsor
K.N. Roy Chengappa
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
DuBois, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Nov 5, 2026, 5:43 AM EST
Completed Not applicable Interventional Results available

A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness

NCT00421304
View directory record Official record
Conditions
RSV Illness in ≤12 Months of Participants
Interventions
Motavizumab, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
0 Months to 12 Months
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
26
States / cities
Tucson, Arizona • Long Beach, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2021 · Synced Nov 5, 2026, 5:43 AM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

NCT04784533
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543, Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Nov 5, 2026, 5:43 AM EST
Withdrawn Not applicable Interventional Accepts healthy volunteers

Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease

NCT00640952
View directory record Official record
Conditions
Parkinson's Disease
Interventions
acamprosate
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2015 · Synced Nov 5, 2026, 5:43 AM EST
Completed Not applicable Interventional

Exogenous Effects of Standard Medical Care (Dopamine) on Motor Learning of an Upper Limb Task in Parkinson Disease

NCT02600858
View directory record Official record
Conditions
Parkinson Disease
Interventions
Upper limb feeding training
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
50 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Nov 5, 2026, 5:43 AM EST
Completed Phase 2 Interventional

Troglitazone in Treating Patients With Liposarcoma

NCT00003058
View directory record Official record
Conditions
Sarcoma
Interventions
troglitazone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Nov 5, 2026, 5:43 AM EST
Completed Not applicable Interventional

Pathways 2 Safety: AI-Simulated Clients for Experiential Learning in Behavioral Health Education

NCT07873658
View directory record Official record
Conditions
Lethal Means Counseling Skill
Interventions
Lethal means counseling training and skills practice
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Nov 5, 2026, 5:43 AM EST
Not listed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Recurrent Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

NCT00004858
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
B43-genistein immunoconjugate
Biological
Lead sponsor
Parker Hughes Cancer Center
Other
Eligibility
Up to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
3
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Nov 5, 2026, 5:43 AM EST
Completed Phase 2 Interventional Results available

Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer

NCT00282048
View directory record Official record
Conditions
Kidney Neoplasms, Carcinoma, Renal Cell
Interventions
AG-013736 (axitinib)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
5
States / cities
Chicago, Illinois • The Bronx, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Nov 5, 2026, 5:43 AM EST
Completed Phase 2 Interventional

Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection

NCT01435044
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Sofosbuvir, GS-0938, RBV, Placebo to match sofosbuvir, Placebo to match GS-0938
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
42
States / cities
Montgomery, Alabama • Bakersfield, California • Coronado, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Nov 5, 2026, 5:43 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Predicting the Diagnosis of Asthma

NCT00620334
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 64 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 10, 2010 · Synced Nov 5, 2026, 5:43 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function

NCT00759564
View directory record Official record
Conditions
Pneumonia
Interventions
CP-70,429 and PF-03709270
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Nov 5, 2026, 5:43 AM EST
Completed Phase 1 Interventional

A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer

NCT02874664
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
Rovalpituzumab Tesirine
Drug
Lead sponsor
Stemcentrx
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
13
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Nov 5, 2026, 5:43 AM EST
Recruiting Phase 2 Interventional

A Study of LAD603 in Adults With Alopecia Areata

NCT07311564
View directory record Official record
Conditions
Alopecia Areata
Interventions
LAD603, Placebo
Drug · Other
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Nov 5, 2026, 5:43 AM EST
Terminated Phase 1 Interventional Results available

Melatonin Postoperative Sleep Study in Breast Cancer Patients

NCT00506064
View directory record Official record
Conditions
Breast Cancer
Interventions
Melatonin, Placebo, Questionnaire
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
40 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Nov 5, 2026, 5:43 AM EST